Reflux

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900–20.

2. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014;63(6):871–80.

3. Yamasaki T, Hemond C, Eisa M, et al. The changing epidemiology of gastroesophageal reflux disease: Are patients getting younger? J Neurogastroenterol Motil 2018;24(4):559.

4. Wyeth JW. Functional gastrointestinal disorders in New Zealand. J Gastroenterol Hepatol 2011;26(s3):15–18.

5. Dean BB, Aguilar D, Johnson LF, et al. The relationship between the prevalence of nighttime gastroesophageal reflux disease and disease severity. Dig Dis Sci 2010;55(4):952–59.

6. Wu JC. Gastroesophageal reflux disease: An Asian perspective. J Gastroenterol Hepatol 2008;23(12):1785–93.

7. Lee SW. Heartburn and regurgitation have different impacts on life quality of patients with gastroesophageal reflux disease. World J Gastroenterol 2014;20(34):12277.

8. Havemann BD, Henderson CA, El-Serag HB. The association between gastro-oesophageal reflux disease and asthma: a systematic review. Gut 2007;56(12):1654–64.

9. Couillard S, Jackson DJ, Wechsler ME, Pavord ID. Workup of severe asthma. Chest 2021;160(6):2019–29.

10. Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 2018;67(3):430–40.

11. Guadagnoli L, Yadlapati R, Taft T, et al. Esophageal hypervigilance is prevalent across gastroesophageal reflux disease presentations. Neurogastroenterol Motil 2021;33(8):e14081.

12. Böhmer AC, Schumacher J. Insights into the genetics of gastroesophageal reflux disease (GERD) and GERD-related disorders. Neurogastroenterol Motil 2017;29(2):10.1111/nmo.13017.

13. Scida S, Russo M, Miraglia C, et al. Relationship between Helicobacter pylori infection and GERD. Acta Biomed 2018;89(8-S):40–43.

14. Wiklund AK, Santoni G, Yan J, et al. Risk of esophageal adenocarcinoma after Helicobacter pylori eradication treatment in a population-based multinational cohort study. Gastroenterology 2024;167(3):485–92.e3.

15. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007;5(1):4–16.

16. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55(10):1398–402.

17. Lei WY, Yu HC, Wen SH, et al. Predictive factors of silent reflux in subjects with erosive esophagitis. Dig Liver Dis 2015;47(1):24–29.

18. Malfertheiner P, Nocon M, Vieth M, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care–the ProGERD study. Aliment Pharmacol Ther 2012;35(1):154–64.

19. Pregun I, Hritz I, Tulassay Z, Herszényi L. Peptic esophageal stricture: Medical treatment. Digestive Diseases 2009;27(1):31–37.

20. Hayeck TJ, Kong CY, Spechler SJ, et al. The prevalence of Barrett’s esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus 2010;23(6):451–57.

21. Shaheen NJ, Richter JE. Barrett’s oesophagus. Lancet 2009;373(9666):850–61.

22. Chandar AK, Low EE, Singer ME, et al. Estimated burden of screening for Barrett’s esophagus in the United States. Gastroenterology 2023;165(1):283–85.e2.

23. Dong J, Grant C, Vuong B, et al. Feasibility and safety of tethered capsule endomicroscopy in patients with Barrett’s esophagus in a multi-center study. Clin Gastroenterol Hepatol 2022;20(4):756–65.e3

24. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97(2):142–46.

25. Ministry of Health. Cancer: Historical summary 1948–2017.

26. Stavrou EP, McElroy HJ, Baker DF, et al. Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972-2005. Med J Aust 2009;191(6):310–14.

27. Visrodia K, Singh S, Krishnamoorthi R, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: A systematic review and meta-analysis. Gastroenterology 2016;150(3):599–607.e7.

28. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349(23):2241–52.

29. Schauer C, Sekra A, Ogra R. Quality of life after oesophageal stenting in patients with palliative oesophageal cancer. N Z Med J 2021;134(1545):106–19.

30. Soeberg M, Blakely T, Sarfati D. Trends in ethnic and socioeconomic inequalities in cancer survival, New Zealand, 1991-2004. Cancer Epidemiol 2015;39(6):860–62.

31. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004;140(7):518–27.

32. Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2016;14(2):175–82.e1–3.

33. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007;(2):CD003244.

34. Statista. Leading chemical substances dispensed in England in 2023, by number of items.

35. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008;336(7634):2–3.

36. Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol 2018;16(6):800–08.e7.

37. Clinical Pharmacogenetics Implementation Consortium. CPIC Guideline for Proton Pump Inhibitors and CYP2C19.

38. Tan CM, Juurlink DN. Navigating drug interactions with proton pump inhibitors. JAMA Netw Open 2024;7(7):e2419818.

39. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019;157(3):682–91.e2.

40. Ren LH, Chen WX, Qian LJ, et al. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol 2014;20(9):2412–19.

41. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007;26(10):1333–44.

42. Wong HJ, Su B, Attaar M, et al. Anti-reflux mucosectomy (ARMS) results in improved recovery and similar reflux quality of life outcomes compared to laparoscopic Nissen fundoplication. Surg Endosc 2021;35(12):7174–82.

43. Kohn GP, Price RR, DeMeester SR, et al. Guidelines for the management of hiatal hernia. Surg Endosc 2013;27(12):4409–28.

44. Salvador R, Vittori A, Capovilla G, et al. Antireflux surgery’s lifespan: 20 years after laparoscopic fundoplication. J Gastrointest Surg 2023;27(11):2325–35.

45. Zhou T, Harnsberger C, Broderick R, et al. Erratum to: Reoperation rates after laparoscopic fundoplication. Surg Endosc 2015;29(3):515–15.

46. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022;117(1):27–56.